Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Migraine
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Migraine
    Combination Drug Taken Early Relieves Migraine Symptoms - (DGNews)
    TopAbstracts in Migraine 07/03/2008 - (DGNews)
    Parenteral dexamethasone for acute severe migraine headache: meta-analysis of randomised controlled trials for preventing recurrence - (BMJ)
    TopAbstracts in Migraine 06/05/2008 - (DGNews)
    TopAbstracts in Migraine 05/08/2008 - (DGNews)

    News archive

     Recent webcasts/CME - Migraine
      Migraine Prevention: What Pharmacists Need to Know
      Update on Migraine Headache

      Webcasts/CME archive

       Recent cases - Migraine
        Acute Bilateral Simultaneous Angle Closure Glaucoma After Topiramate Administration
        A Case of Intermittent Ataxia Associated with Migraine Headaches
        Pneumatized Superior Turbinate as a Cause of Headache
        Transient Monocular Visual Loss and Retinal Migraine
        Hemeplegic Migraine with Leptomeningeal Angiomatosis

        Cases archive
          




        my personal edition > migraine > news
        divider

          E-Mail this DGDispatch to a colleague

        DGDispatch


        Topiramate Shows Promise for Migraine Prevention in Teenagers: Presented at AAN

        By Jill Stein

        SAN FRANCISCO, CA -- April 29, 2004 -- Topiramate may help stave off migraines in adolescents, researchers reported here on April 27th at the American Academy of Neurologists 56th Annual Meeting.

        Paul Winner, DO, Director, Palm Beach Headache Center, West Palm Beach, Florida, described the results of a post-hoc analysis performed on efficacy and safety data obtained from patients 12 to 18 years of age who were enrolled in three large randomised, double-blind, placebo-controlled trials of topiramate 50, 100, and 200 mg/day.

        The double-blind phase of these trials included titration and maintenance periods. During the titration phase, which lasted up to 8 weeks, the initial dose of topiramate of 25 mg/day was increased in weekly increments of 25 mg/day until patients reached the assigned or maximum tolerated dose, whichever was lower.

        The titration phase was followed by an 18-week maintenance phase during which patients were allowed only one dose reduction due to tolerability problems.

        All participants had 3 to 12 migraine periods but no more than 15 headache days during the baseline phase. The trial excluded patients with chronic daily headache, defined as headache for 15 or more days per months.

        Results in 55 evaluable patients showed that topiramate at a dose of 100 mg/day was associated with decreases in mean monthly migraine frequency, migraine days, and acute medication use. Migraine frequency was decreased by at least 50% in 62% of patients who received topiramate at a dose of 100 mg/day versus 21% of placebo-treated patients.

        The100 mg/day dose was associated with a statistically significant reduction in monthly acute medication use (P =.042), and with reductions in monthly migraine frequency and migraine days.

        Topiramate was generally well tolerated in this population, with paresthesia, upper respiratory tract infection, and weight loss among the most common treatment-emergent adverse events. The overall incidence of adverse effects was less than that observed in the adult population in these trials.

        Dr. Winner emphasised that larger trials are needed to corroborate the findings.

        The trial was sponsored by Johnson and Johnson Pharmaceutical Research and Development, Raritan, New Jersey.


        [Presentation title: Topiramate for Migraine Prevention in Adolescent Patients. Poster P02.102]



        E-Mail this DGDispatch to a colleague   To print, use this version






        All contents Copyright (c) 1995-2008 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send